Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 23^rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Berlin, Germany from April 27-30, 2013. The following posters will be presented: Saturday, April 27, 2013 15:30 - 16:30 Title:A study to evaluate the safety, tolerability, and pharmacokinetics of multiple weekly doses of intravenous dalbavancin in healthy subjects Authors: M. Dunne, C. Sprenger, S. Moriarty (Branford, US) Poster #: P910 Sunday, April 28, 2013 13:30 - 14:30 Title:Dalbavancin activity in the USA: reported from the SENTRY Programme (2012) Authors: R.N. Jones, R.K. Flamm, H.S. Sader, B.P. Goldstein, M. Dunne (North Liberty, Morristown, US) Poster #: P1646 Copies of these posters will be available on Durata's website following the ECCMID Meeting:www.duratatherapeutics.com. About Dalbavancin Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Forward-looking Statements Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. CONTACT: Investor Relations and Public Affairs Contact Allison Wey Durata Therapeutics Vice President, Investor Relations and Public Affairs (312) 219-7017 firstname.lastname@example.org Media Relations Contact Jed Weiner White Oak Communications, Inc. (847) 392-4186 email@example.com Durata Therapeutics, Inc. Logo
Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting
Press spacebar to pause and continue. Press esc to stop.